Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth

HONG KONG, Aug. 26, 2026 /PRNewswire/ -- On August 26, 2026, Viva Biotech Holdings Group ("the Group" or "the Company", stock code: 1873.HK) announced that the Group's revenue amounted to RMB1,006.5 million and gross profit of RMB341.7 million, representing a gross margin of 34.0%. Overall, the Group's total revenue grew by approximately 21.0% year-on-year, primarily driven by the significant contribution from Langhua Pharmaceutical's CDMO business, under which one peptide project has entered the commercial production phase and the other small-molecule project has reached the PPQ phase.